Celgene to buy remaining stake in Juno for $9 billion
January 22, 2018 at 06:39 AM EST
Jan 22 (Reuters) - Celgene Corp said on Monday it agreed to buy rest of Juno Therapeutics Inc for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.
